Literature DB >> 23666504

Enzyme-linked immunosorbent/chemiluminescence assays, recombinant immunoblot assays and nucleic acid tests in the diagnosis of HCV infection.

Robério Amorim de Almeida Pondé1.   

Abstract

The diagnosis of hepatitis C virus (HCV) infection is defined according to the results obtained from screening assays, and confirmation made by supplemental tests, in order to exclude the possibility of false-positive and false-negative results and, therefore, a misdiagnosis. Identifying the patient's true clinical status is of crucial importance to direct an accurate course of therapy, but, often, the definition of this status is only possible after conjunctions and analysis of the results obtained from each methodology applied, considering the limitations of each assay. In this manuscript, it is discussed briefly the possible results obtained from the three methods most commonly applied in routine laboratory and their contribution in the diagnosis of HCV infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23666504     DOI: 10.1007/s10096-013-1857-1

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  21 in total

1.  Misclassification of HCV-viremic blood donors as indeterminate by RIBA 3.0 because of human superoxide dismutase reactivity.

Authors:  L H Tobler; S L Stramer; S H Kleinman; J P Brodsky; D S Todd; M P Busch
Journal:  Transfusion       Date:  2001-12       Impact factor: 3.157

2.  Limits of diagnostic accuracy of anti-hepatitis C virus antibodies detection by ELISA and immunoblot assay.

Authors:  Anatoly P Suslov; Stanislav N Kuzin; Tatiana V Golosova; Nina V Shalunova; Nikolai A Malyshev; Natalia V Sadikova; Lubov M Vavilova; Anna V Somova; Elena E Musina; Maria V Ivanova; Tatiana T Kipor; Igor M Timonin; Lubov E Kuzina; Mihail A Godkov; Alexei I Bajenov; Vladimir G Nesterenko
Journal:  Russ J Immunol       Date:  2002-07

3.  HIV-1, HCV and HBV seronegative window reduction by the new Roche cobas TaqScreen MPX test in seroconverting donors.

Authors:  Michael Wiedmann; Sabine Kluwick; Martina Walter; Gabriele Fauchald; Joerg Howe; Martina Bronold; Michael Zauke
Journal:  J Clin Virol       Date:  2007-07-05       Impact factor: 3.168

4.  Evaluation of the new ARCHITECT anti-HCV screening test under routine laboratory conditions.

Authors:  Annemarie Berger; Holger Rabenau; Regina Allwinn; Hans Wilhelm Doerr
Journal:  J Clin Virol       Date:  2008-07-16       Impact factor: 3.168

5.  Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1991-04-19

6.  Long-term virological follow up of patients with occult hepatitis C virus infection.

Authors:  Inmaculada Castillo; Javier Bartolomé; Juan A Quiroga; Guillermina Barril; Vicente Carreño
Journal:  Liver Int       Date:  2011-08-09       Impact factor: 5.828

7.  Evaluation and comparison of three different anti-hepatitis C virus antibody tests based on chemiluminescence and enzyme-linked immunosorbent assay methods used in the diagnosis of hepatitis C infections in Turkey.

Authors:  Recep Kesli; M Ozdemir; M G Kurtoglu; M Baykan; B Baysal
Journal:  J Int Med Res       Date:  2009 Sep-Oct       Impact factor: 1.671

8.  Comparison of two automated nucleic acid testing systems for simultaneous detection of human immunodeficiency virus and hepatitis C virus RNA and hepatitis B virus DNA.

Authors:  Angelo R Margaritis; Stewart M Brown; Clive R Seed; Philip Kiely; Bruno D'Agostino; Anthony J Keller
Journal:  Transfusion       Date:  2007-10       Impact factor: 3.157

9.  Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA.

Authors:  C Giachetti; J M Linnen; D P Kolk; J Dockter; K Gillotte-Taylor; M Park; M Ho-Sing-Loy; M K McCormick; L T Mimms; S H McDonough
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

10.  Is it possible to diagnose acute hepatitis C virus (HCV) infection by a rising anti-HCV titre rather than by seroconversion?

Authors:  S-N Lu; H-D Tung; T-M Chen; C-M Lee; J-H Wang; C-H Hung; C-H Chen; C-S Changchien
Journal:  J Viral Hepat       Date:  2004-11       Impact factor: 3.728

View more
  5 in total

1.  Retrospective analysis on the diagnostic performances and signal-to-cut-off ratios of the Elecsys Anti-HCV II assay.

Authors:  Banseok Kim; Hyo Jun Ahn; Min Hyuk Choi; Yongjung Park
Journal:  J Clin Lab Anal       Date:  2017-02-10       Impact factor: 2.352

2.  Peptide ligand-based ELISA reagents for antibody detection.

Authors:  Ewa Heyduk; Rachel Hickey; Nicola Pozzi; Tomasz Heyduk
Journal:  Anal Biochem       Date:  2018-08-18       Impact factor: 3.365

Review 3.  Hepatitis C.

Authors:  Daniel P Webster; Paul Klenerman; Geoffrey M Dusheiko
Journal:  Lancet       Date:  2015-02-14       Impact factor: 79.321

4.  Eu3+ /Sm3+ dual-label time-resolved fluoroimmunoassay for measurement of hepatitis C virus antibodies.

Authors:  Xue Yang; Yan Ye; Tingting Wang; Mei Li; Lei Yu; Min Xia; Jun Qian; Zhigang Hu
Journal:  J Clin Lab Anal       Date:  2018-08-26       Impact factor: 2.352

Review 5.  Seronegative hepatitis C virus infection.

Authors:  Justyna Kaźmierczak; Agnieszka Pawełczyk; Kamila Caraballo Cortes; Marek Radkowski
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2013-11-09       Impact factor: 4.291

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.